Sign In
Buy BETRF
$0.0471
+0.0041 (+9.53%)
At Close: Jun 03, 2026
BetterLife Pharma applies for patent protection for new 2-bromo-LSD compositions, including TD-0148A
08:37am, Monday, 27'th Sep 2021
BetterLife Pharma Inc told investors it had applied for a patent for new compositions of 2-bromo-LSD to use as a treatment for cluster headaches and other neurological conditions. One of these composi
BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders
08:00am, Monday, 27'th Sep 2021
VANCOUVER, British Columbia, Sept. 27, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focu
BetterLife Pharma enrolls first patient in interferon alpha-2b COVID-19 trial in Chile
10:11am, Wednesday, 22'nd Sep 2021
BetterLife Pharma Inc said its wholly owned subsidiary Altum Pharmaceuticals Inc along with Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of the Phas
BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
08:00am, Wednesday, 22'nd Sep 2021
VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ) today announced that its
BetterLife Pharma strikes research agreement with Medical College Wisconsin for its TD-0148A neurological receptor studies
09:58am, Thursday, 09'th Sep 2021
BetterLife Pharma Inc. has announced an agreement with the Laboratory of Dr John McCorvy at the Medical College of Wisconsin (MCW) for TD-0148A preclinical neurological receptor binding studies.
Betterlife Pharma announces start of pre-clinical study of AP-003 against COVID-19's Delta variant
09:08am, Wednesday, 25'th Aug 2021
BetterLife Pharma Inc revealed that a pre-clinical study of its interferon AP-003 candidate to tackle the Delta variant of coronavirus (COVID-19) had started at the ImPaKT Facility at Western Universi
BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) against Delta Variant of SARS-CoV-2
08:00am, Wednesday, 25'th Aug 2021
VANCOUVER, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotechnology
BetterLife Pharma Inc announced that its wholly-owned subsidiary, Altum Pharmaceuticals Inc, and Pontificia Universidad Católica de Chile have obtained approval to conduct their planned randomized pl
BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile
08:00am, Tuesday, 27'th Jul 2021
VANCOUVER, British Columbia, July 27, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ) today announced that its wh
BetterLife Pharma secures Mitacs Accelerate funding to research its chronic anxiety and depression candidate
11:41am, Thursday, 22'nd Jul 2021
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF)'s bid to advance its TD-010 candidate to treat chronic anxiety and depression has been boosted by a funding award. The biotech revealed it had been grant
BetterLife Pharma secures Mitacs Accelerate program to research its chronic anxiety and depression candidate
10:47am, Thursday, 22'nd Jul 2021
BetterLife Pharma Inc's bid to advance its TD-010 candidate to treat chronic anxiety and depression has been boosted by a funding award. The biotech revealed it had been granted Mitacs Accelerate pro
BetterLife Pharma says early positive in vitro results show AP-003 has similar potent efficacy against coronavirus variants
10:14am, Thursday, 15'th Jul 2021
BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) has announced early positive in vitro results of its SARS-CoV-2 (COVID-19) anti-viral, recombinant human interferon alpha-2b (rhIFN⍺2b or AP
BetterLife Pharma says it expects to start human trials on non-hallucinogenic LSD compound TD-0148A in 2022
11:00am, Monday, 12'th Jul 2021
BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) issued a progress update on its drug pipeline for the treatment of mental health disorders, which includes a non-hallucinogenic LSD compound.
BetterLife Pharma has a promising pipeline of psychedelic products, a coronavirus nebulizer and AP-001 cream
01:43pm, Monday, 28'th Jun 2021
Three compelling and differentiated assets Potential coronavirus treatment AP-003's Phase 2 trial to start in 2Q 2021 Management team led by veteran entrepreneur CEO Dr Ahmad Doroudian What BetterLife
BetterLife Pharma announces partial exercise of over-allotment option to raise $2.8 million
10:44am, Friday, 25'th Jun 2021
BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU ) has announced the partial exercise of the over-allotment option with its $2,610,000 marketed public offering that closed on June 7. In a stat
